Heart implant

Abstract

The present disclosure relates to a cardiac implant. The cardiac implant includes a treatment device and at least one sensor. The treatment device is configured to repair the function of a valve to prevent blood from flowing back from a second chamber to a first chamber, and the at least one sensor is attached to the treatment device and configured to sense physiological information of a patient. The cardiac implant provided by the present disclosure can not only improve the regurgitation condition of the patient to achieve the treatment purpose, but also sense the physiological information of the patient's heart to achieve the monitoring purpose. By using the cardiac implant provided by the present disclosure, the patient needs to go to the hospital for regular reexamination less frequently or not at all. Thus, the cardiac implant provided by the present disclosure can reduce the economic burden and time cost of the patient. In addition, in the present disclosure, the sensor is positioned in the patient's heart by being attached to the treatment device, rather than being directly anchored to the patient's heart tissue, which reduces tissue damage.

Description

Technical Field

[0001] The present disclosure relates to the technical field of medical devices, and particularly to a cardiac implant. Background Art

[0002] Cardiac valves refer to the valves between the atria and ventricles or between the ventricles and arteries. The valves play a key role in the never - stopping blood circulation in the heart. After the blood flows through, the valves will close, thus preventing blood from flowing back. Several structural factors may affect the proper closure of the cardiac valves, thereby causing blood reflux. Taking the mitral valve as an example, if the mitral valve cannot close properly, it will cause blood to flow from the left ventricle through the mitral valve into the left atrium during ventricular systole, thereby damaging the health of the patient.

[0003] In order to improve the blood reflux situation, some implants suitable for being implanted into the heart of a patient have emerged. These implants can be delivered surgically between the leaflets of the patient's valve to improve the closure of the valve, thereby reducing the likelihood of blood reflux. Current implants often affect the structure of the existing valve, including its support structure, while repairing and improving the valve closure, thus causing some hemodynamic and / or clinical problems.

[0004] After the implant is implanted into the patient's heart, the patient usually needs to go to the hospital for regular follow - up. Generally speaking, the purposes of regular follow - up are in two aspects. On the one hand, it is to observe the effect of the implant on cardiac function (such as whether it is improved, etc.) and the working condition of the implant, and whether there are any adverse events related to the implant. On the other hand, it is to check the overall condition of the patient, such as heart failure, drug use, etc., to determine whether the patient's condition has been effectively improved or whether there has been a further deterioration. These follow - ups basically need to be carried out in the hospital (or clinic). Frequent follow - ups, especially for patients in remote areas, increase the economic burden on the patient and raise the patient's time cost. At the same time, since the follow - up time intervals are generally long and the changes in the condition are often unpredictable, it is more difficult to achieve the goal of early detection of problems, reducing / diminishing the deterioration of the condition, and improving the patient's quality of life. Summary of the Invention

[0005] In view of this, the present disclosure provides a cardiac implant.

[0006] The cardiac implant is suitable for being implanted into the heart of a patient. The patient's heart includes a first chamber, a second chamber, and a valve, and the valve is used to periodically allow blood to flow from the first chamber into the second chamber. The cardiac implant includes a treatment device and at least one sensor. The treatment device is used to repair the function of the valve to prevent blood from flowing back from the second chamber to the first chamber, and at least one sensor is attached to the treatment device and is used to sense the physiological information of the patient.

[0007] In a possible implementation, the valve includes a pair of leaflets, the treatment device includes a pad, the pad is configured to be located between the pair of leaflets and to cause the valve to open and close periodically by cooperating with the pair of leaflets, and at least one sensor is attached to the pad.

[0008] In a possible implementation, the pad has a top surface configured to face the first chamber, and at least one sensor includes a sensor attached to the top surface of the pad to sense the blood pressure in the first chamber.

[0009] In a possible implementation, the pad has a bottom surface configured to face the second chamber, and at least one sensor includes a sensor attached to the bottom surface of the pad to sense the blood pressure in the second chamber.

[0010] In a possible implementation, the pad has a top surface configured to face the first chamber and a bottom surface configured to face the second chamber, and at least one sensor includes a pair of sensors respectively attached to the top surface and the bottom surface of the pad to respectively sense the blood pressure in the first chamber and the second chamber.

[0011] In a possible implementation, the treatment device includes a support configured to be located in the first chamber and connected to the pad to position the pad between the pair of leaflets, wherein at least one sensor is attached to the support.

[0012] In a possible implementation, the heart valve includes a pair of leaflets, the treatment device includes an abutment and a pair of paddles respectively located on opposite sides of the abutment, and the pair of paddles are configured to position the abutment between the pair of leaflets.

[0013] In a possible implementation, the abutment has a top surface configured to face the first chamber, and at least one sensor includes a sensor attached to the top surface of the abutment to sense the blood pressure in the first chamber.

[0014] In a possible implementation, the treatment device has a bottom surface configured to face the second chamber, and at least one sensor includes a sensor attached to the bottom surface of the treatment device to sense the blood pressure in the second chamber.

[0015] In a possible implementation, the abutment has a top surface configured to face the first chamber, the treatment device has a bottom surface configured to face the second chamber, and at least one sensor includes a pair of sensors respectively attached to the top surface of the abutment and the bottom surface of the treatment device to respectively sense the blood pressure in the first chamber and the second chamber.

[0016] In a possible implementation, at least one sensor is at least one pressure sensor.

[0017] The cardiac implant provided by the present disclosure can not only improve the patient's reflux condition to achieve the treatment purpose, but also sense the physiological information of the patient's heart to achieve the monitoring purpose. Since the sensor can provide hemodynamic information (such as pressure) of the patient in the atrium and / or ventricle (especially the left atrium and / or left ventricle), it makes it possible for doctors to remotely obtain this information as needed. This enables patients to need to visit the hospital for follow-up less frequently or not at all, and enables early understanding of the patient's condition, including the effect of the implant and / or changes in the course of the disease, making early detection, early diagnosis, and early treatment possible. Thus, the cardiac implant provided by the present disclosure can reduce the economic burden and time cost of patients. In addition, in the present disclosure, the sensor is positioned in the patient's heart by being attached to the treatment device, rather than being directly anchored to the patient's heart tissue, which reduces damage to the heart tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] To more clearly illustrate the technical solutions of the embodiments of the present disclosure, the drawings required for use in the embodiments will be briefly introduced below.

[0019] It should be understood that the following drawings only show some embodiments of the present disclosure, and thus should not be regarded as limiting the scope. For those of ordinary skill in the art, other related drawings can be obtained based on these drawings without creative efforts.

[0020] It should be understood that the same or similar reference numerals are used in the drawings to represent the same or similar elements (components or parts).

[0021] It should be understood that the drawings are only schematic, and the sizes and proportions of the elements (components or parts) in the drawings are not necessarily accurate.

[0022] Figure 1 is a schematic structural diagram of a cardiac implant according to an embodiment of the present disclosure.

[0023] Figure 2 is a schematic structural diagram showing the cardiac implant as shown Figure 1 inside the patient's heart.

[0024] Figure 3 is a schematic structural diagram showing the cardiac implant according to another embodiment of the present disclosure inside the patient's heart.

[0025] Figure 4 is a schematic structural diagram showing the cardiac implant according to another embodiment of the present disclosure inside the patient's heart.

[0026] Figure 5 is a schematic structural diagram showing the cardiac implant according to another embodiment of the present disclosure inside the patient's heart.

[0027] Figure 6 is a schematic structural diagram of a cardiac implant according to another embodiment of the present disclosure located within a patient's heart. Detailed implementation manners

[0028] The technical solutions in the embodiments of the present disclosure will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present disclosure. Obviously, the described embodiments are only a part of the embodiments of the present disclosure, rather than all of the embodiments.

[0029] Reference is made below Figure 1 and Figure 2 to describe a cardiac implant 100 according to an embodiment of the present disclosure. Figure 1 is a schematic structural diagram of the cardiac implant 100. Figure 2 is a schematic structural diagram of the cardiac implant 100 located at a valve within a patient's heart.

[0030] It should be noted that in the accompanying drawings of the present disclosure, the valve is located between a first chamber and a second chamber. The valve is configured to periodically allow blood flow from the first chamber into the second chamber and prevent the reverse flow. The valve includes a pair of mating leaflets FL, SL.

[0031] In particular, the valve may be a mitral valve. Correspondingly, the first chamber may be the left atrium, the second chamber may be the left ventricle, and one of the pair of leaflets FL, SL may be the anterior leaflet and the other may be the posterior leaflet. It should be understood that the cardiac implant provided by the present disclosure is not limited to being applied to the mitral valve, and may also be applied to other heart valves (e.g., the tricuspid valve).

[0032] Referring to Figure 1 and Figure 2 , the cardiac implant 100 includes a treatment device 110 and a pair of sensors 120a, 120b. It can be understood that in other examples, the cardiac implant 100 may also include only one sensor, or may include three or more sensors. The treatment device 110 is configured to repair the function of the valve to prevent blood from regurgitating from the second chamber to the first chamber. The implementation manner of the treatment device 110 will be described in detail below. The pair of sensors 120a, 120b are attached to the treatment device 110. The pair of sensors 120a, 120b are configured to sense the physiological information of the patient.

[0033] Exemplarily, the physiological information may, but is not limited to, include one or more of blood pressure information, blood flow rate information, blood pH information, blood temperature information, blood oxygen information, electrocardiogram information, heart sound information, heart acceleration information, and heart contractility information in the patient's heart. Correspondingly, the sensor in the present disclosure may be a sensor capable of sensing one or more of the above information.

[0034] The cardiac implant provided by the present disclosure can not only improve the patient's regurgitation condition to achieve the treatment purpose, but also sense the physiological information of the patient's heart to achieve the monitoring purpose. By using the cardiac implant provided by the present disclosure, the patient needs to go to the hospital for follow-up less frequently or not at all. Thus, it can be seen that the cardiac implant provided by the present disclosure can reduce the economic burden and time cost of the patient. In addition, in the present disclosure, at least one sensor is positioned in the patient's heart by being attached to the treatment device, rather than being directly anchored to the patient's heart tissue, which reduces tissue damage.

[0035] For the heart of a healthy person, a pair of leaflets FL, SL can naturally close and separate with the cardiac cycle to periodically close and open the valve, thereby allowing blood to flow from the first chamber into the second chamber and preventing reverse flow. However, for a patient with valvular insufficiency, when the valve needs to be closed, a pair of leaflets FL, SL cannot achieve proper closure, and there is a gap between them, allowing blood flow to pass through the valve from the second chamber into the first chamber, causing regurgitation.

[0036] Continue to refer to Figure 1 and Figure 2 , the treatment device 110 includes a pad 111. After the cardiac implant 100 is implanted into the patient's heart, the pad 111 is configured to be located between a pair of leaflets FL, SL. The pad 111 is configured to cooperate with a pair of leaflets FL, SL to periodically open and close the valve, thereby allowing blood to flow from the first chamber into the second chamber and preventing reverse flow. A pair of acquisition devices 120a, 120b are attached to the pad 110 to facilitate the fixation of the pair of acquisition devices 120a, 120b.

[0037] Refer back to Figure 1 and Figure 2 , the pad 111 includes a top surface 111a facing the first chamber and a bottom surface 111b facing the second chamber. A pair of sensors 120a, 120b may be a pair of pressure sensors 120a, 120b. A pair of pressure sensors 120a, 120b may be respectively attached to the top surface 111a and the bottom surface 111b of the pad 111 to respectively sense the blood pressure information of the first chamber and the second chamber.

[0038] Pressure sensors 120a and 120b can sense the blood pressure throughout the cardiac cycle in the first chamber and the second chamber respectively, providing hemodynamic information with diagnostic value for doctors. This information plays an important role in evaluating the overall function of the heart, as well as the working conditions of the valves and the implants. At the same time, the pressure information can also help doctors evaluate the placement position of the implant during the implantation process and make a real-time assessment of whether there is an obstruction to the diastolic blood flow into the second chamber, thus better ensuring the success of the implantation surgery and achieving better clinical effects.

[0039] In addition, when the valve is open, the blood flow from the first chamber to the second chamber can impact the diaphragm of the pressure sensor 120a attached to the top surface 111a almost head-on. This enables the physiological information (i.e., blood pressure information) sensed by the pressure sensor 120a to reflect whether the blood flow from the first chamber to the second chamber is normal, and thus can relatively accurately reflect whether there is a stenosis problem with the patient's valve after the cardiac implant 100 is implanted.

[0040] When the valve is closed, if there is still a backflow from the second chamber to the first chamber, the backflow will impact the diaphragm of the pressure sensor 120b attached to the bottom surface 111b almost head-on. As a result, the physiological information and changes (i.e., pressure information) generated by the blood flow sensed by the sensor 120b, including whether there is a backflow from the second chamber to the first chamber, can be detected.

[0041] Thus, through a pair of pressure sensors 120a and 120b respectively attached to the top surface 111a and the bottom surface 111b of the pad 111, it is possible to relatively accurately detect whether there is a stenosis problem or a backflow problem with the valve after the cardiac implant 100 is implanted, and thus can relatively accurately monitor the patient's postoperative recovery degree and the development of the condition.

[0042] It should be noted that although in the foregoing embodiment, the cardiac implant 100 includes a pair of sensors 120a and 120b, in other examples, the cardiac implant 100 may also include only the sensor 120a attached to the top surface 111a, or may include only the sensor 120b attached to the bottom surface 111b. Of course, in other examples, the cardiac implant 100 may also include more sensors.

[0043] It should also be noted that although in the foregoing embodiment, a pair of sensors 120a and 120b are respectively attached to the top surface 111a and the bottom surface 111b of the pad 111, in other examples, a pair of sensors 120a and 120b may also be attached to other parts of the pad 111. For example, in some examples, one or more sensors may be attached to the side surface of the pad 111.

[0044] Continue to refer toFigure 1 and Figure 2 The cushion 111 also has a pair of mating surfaces 111c and 111d. The pair of mating surfaces 111c and 111d are configured to face a pair of leaflets FL and SL respectively. As the cardiac cycle changes, each of the pair of mating surfaces 111c and 111d mates with and separates from the leaflet it faces periodically, so that the valve opens and closes periodically. In particular, when one of the mating surfaces 111c and 111d mates with its corresponding leaflet, the coaptation length therebetween can range from 6 to 12 millimeters. In particular, the leaflet FL can be the anterior leaflet, the leaflet SL can be the posterior leaflet, and the cushion 111 can be configured to be closer to the leaflet SL than to the leaflet FL. In particular, the mating surfaces 111c and 111d can be smoothly transitioning curved surfaces to reduce the resistance to blood flow.

[0045] When the second chamber is in diastole, the pair of leaflets FL and SL move away from each other, forming channels between the pair of leaflets FL and SL and the pair of mating surfaces 111c and 111d respectively; at this time, the valve opens and blood flow can pass through these channels from the first chamber into the second chamber. When the second chamber is in systole, the pair of leaflets FL and SL move towards each other, causing the pair of leaflets FL and SL to mate with the pair of mating surfaces 111c and 111d respectively; at this time, the valve closes and blood flow from the second chamber to the first chamber is blocked. It should be noted that in the present disclosure, when the leaflet mates with the mating surface, the leaflet and the mating surface can contact to prevent blood flow from flowing between them.

[0046] In this implementation, the cushion 111 does not affect or less affects the movement of the pair of leaflets FL and SL, and both of the pair of leaflets FL and SL can maintain their original physiological functions. That is to say, in this implementation, as the cardiac cycle changes, both of the pair of leaflets FL and SL can move towards and away from each other naturally and periodically. Therefore, by using the treatment device according to this implementation, it can less, or even not, bring adverse effects to the structures and functions of the leaflets FL and SL. That is to say, by using the cardiac implant 100 provided in the present disclosure, there is no restriction or obstruction to the spontaneous movement (closing, opening) of the valve, and there is no association with the supporting structure of the valve, and no corresponding adverse effects will be generated.

[0047] Continue to refer to Figure 1 and Figure 2, the treatment device 110 may further include a support member 112. After the heart implant 100 is implanted into a patient's heart, the support member 112 is located within the first chamber and connected to the pad 111, thereby positioning the pad 111 between a pair of leaflets SL, FL. Through the support member 112 located within the first chamber, the pad 111 can be reliably positioned between a pair of leaflets FL, SL. In particular, the connection position of the support member 112 to the pad 111 is configured to be adjustable such that the position of the pad between FL and SL can be adjusted.

[0048] Continue to refer to Figure 1 and Figure 2 , the support member 112 may be annular. After the heart implant 100 is implanted into a patient's heart, the support member 112 may be disposed at the annulus of the heart. In some embodiments, the support member 112 may have a grid structure. During delivery, the support member 112 may first be folded to reduce its volume; after the support member 112 is delivered to the target location, it may then be unfolded.

[0049] It can be understood that the implementation of the support member 112 is not limited to the above, as long as it can achieve positioning the pad 111 between a pair of leaflets FL, SL of the valve. For example, in some embodiments, the support member 112 may also be semi-annular or partially annular.

[0050] Figure 3 is a schematic structural view of a heart implant 200 according to another embodiment of the present disclosure located within a patient's heart. The heart implant 200 is substantially the same as the heart implant 100. For the sake of brevity, the same parts will not be described again.

[0051] Refer to Figure 3 , the heart implant 200 includes a treatment device 210. The treatment device 210 includes a pad 211 and a support member 212. The pad 211 is substantially the same as the pad 111 in the foregoing embodiment, and the support member 212 is substantially the same as the support frame 112 in the foregoing embodiment. The relevant descriptions of the pad 211 and the support member 212 can refer to the descriptions of the pad 111 and the support member 112 in the foregoing embodiment.

[0052] The cardiac implant 200 further includes a sensor 220. The sensor 220 is attached to the support member 212 and is configured to sense the physiological information of the patient. In particular, the sensor 220 can be a pressure sensor. In particular, the sensor 220 can be attached to a portion of the support member 212 closer to the body surface, such as closer to the anterior, left, or posterior chest wall. In particular, the sensor 220 can be attached to the support member 212 and the relative positions of the two can be configured such that the support member 212 is not located between the sensor 220 (at least the communication portion of the sensor 220) and an extracorporeal device communicating with the sensor 220. This minimizes the interference of the support member 212 (especially when made of metal) on the wireless communication between the extracorporeal device and the sensor.

[0053] It should be understood that although only one sensor 220 is shown in Figure 3 , the cardiac implant 200 can also include multiple sensors. The multiple sensors can be respectively attached to different parts of the support member 212. Alternatively, a part of the multiple sensors can be attached to the support member 212, and another part can be attached to the pad 211.

[0054] Figure 4 is a schematic structural diagram showing a cardiac implant 300 according to another embodiment of the present disclosure located in a patient's heart. The cardiac implant 300 is substantially the same as the cardiac implant 100. For the sake of brevity, the same parts will not be described again.

[0055] See Figure 4 , the cardiac implant 300 includes a treatment device 310 and a pair of sensors 320a, 320b. The treatment device 310 includes a pad 311, and the pad 311 has a top surface 311a and a bottom surface 311b facing the first chamber and the second chamber respectively. The pair of sensors 320a, 320b can be a pair of pressure sensors 320a, 320b, and the pair of pressure sensors 320a, 320b can be respectively attached to the top surface 311a and the bottom surface 311b.

[0056] It should be noted that in other examples, the cardiac implant 300 can also include only one of the pair of sensors 320a, 320b. It should also be noted that in other examples, the sensors of the cardiac implant 300 can also be attached to places other than the top surface 311a and the bottom surface 311b of the pad 311, for example, attached to the support frame. It should also be noted that in other examples, the sensors of the cardiac implant 300 can also be sensors capable of sensing other physiological information.

[0057] The mating mode of the pad 311 with a pair of leaflets FL, SL is different from that of the pad 111 with a pair of leaflets FL, SL in the foregoing embodiment. Specifically, the pad 311 includes a pair of mating surfaces 311c, 311d. When the cardiac implant 300 is implanted into a patient's heart, the pad 311 is configured to be located between a pair of leaflets FL, SL and follow the movement of the leaflet SL, and the pair of mating surfaces 311c, 311d are configured to face a pair of leaflets FL, SL respectively. As the pad 311 follows the movement of the leaflet SL, the mating surface 311d is configured to remain in alignment with the leaflet SL (for example, the value range of the alignment length therebetween can be 6 to 12 millimeters), and the mating surface 311c is configured to periodically mate with and separate from the leaflet FL. That is to say, along with the change of the cardiac cycle, the mating surface 311d always remains in alignment with the leaflet SL, while the mating surface 311c periodically mates with and separates from the leaflet FL.

[0058] In this implementation, the pad 311 does not affect or less affects the movement of a pair of leaflets FL, SL, and both leaflets FL, SL can maintain their original physiological functions, especially the leaflet FL. That is to say, in this implementation, along with the change of the cardiac cycle, both leaflets FL, SL can relatively move and move away naturally and periodically. Thus, it can be seen that this implementation can less bring adverse effects to the structures and functions of the leaflets FL, SL.

[0059] There are various ways to position the pad 311 between a pair of leaflets FL, SL and make the pad 311 follow the movement of the leaflet SL, and the present disclosure does not make specific limitations thereto. As an example, continue to refer to Figure 4 , the treatment device 310 further includes a staple 312. The staple 312 can penetrate the leaflet SL to attach the pad 311 to the leaflet SL, so that the pad 311 is located between a pair of leaflets FL, SL and follows the movement of the leaflet SL. In this way, along with the change of the cardiac cycle, the mating surface 311d facing the leaflet SL can remain in alignment with the leaflet SL, and the mating surface 311c facing the leaflet FL can periodically mate with and separate from the leaflet FL as the pad 311 follows the movement of the leaflet SL.

[0060] It should be noted that the treatment device 310 can include only one staple 312 or can include multiple staples 312, and the present disclosure does not make specific limitations thereto. The staple 312 can be integrally formed with the pad 311, or the two can be two independent components, and the embodiments of the present disclosure also do not make specific limitations thereto.

[0061] Figure 5 is a schematic structural view showing a cardiac implant 400 according to another embodiment of the present disclosure located in a patient's heart. The cardiac implant 400 is substantially the same as the cardiac implant 100. For the sake of brevity, the same parts will not be described again.

[0062] See Figure 5 , the heart implant 400 includes a treatment device 410 and a pair of sensors 420a, 420b. The treatment device 410 includes a pad 411 and a support 412 for positioning the pad 411 between a pair of leaflets FL, SL. The support 412 is substantially the same as the support 112 in the foregoing embodiments. The pad 411 has a top surface 411a and a bottom surface 411b facing the first chamber and the second chamber, respectively. The pair of sensors 420a, 420b can be a pair of pressure sensors 420a, 420b, and the pair of pressure sensors 420a, 420b can be attached to the top surface 411a and the bottom surface 411b, respectively. Additionally, the connection between the support 412 and the pad 411 can be configured to be movable so that during the cardiac cycle, the pad 411 can move with the leaflet SL.

[0063] It should be noted that in other examples, the heart implant 400 may also include only one of the pair of sensors 420a, 420b. It should also be noted that in other examples, the sensors of the heart implant 400 can also be attached to places other than the top surface 411a and the bottom surface 411b of the pad 411. For example, in some examples, the heart implant 400 can include at least one sensor attached to the support 412. It should also be noted that in other examples, the sensors of the heart implant 400 can also be sensors capable of sensing other physiological information.

[0064] The pad 411 also has a pair of mating surfaces 411c, 411d. The pair of mating surfaces 411c, 411d are configured to face a pair of leaflets FL, SL, respectively. When the heart implant 400 is implanted into a patient's heart, the pad 411 is rigidly connected to the support 412 (i.e., the two are connected in a non-relatively movable manner), so that the pad 411 is held at a preset position between the pair of leaflets FL, SL and the mating surface 411d is in alignment with the leaflet SL. The preset position is configured such that the mating surface 411c can periodically mate with and separate from the leaflet FL as the leaflet FL moves. During systole, the leaflet FL mates with the mating surface 411c and reaches a certain mating length (such as 6 - 12 mm), increasing the effective closure of the leaflet and preventing blood flow from flowing from the second chamber into the first chamber; during diastole, the leaflet FL opens, and blood flows from the first chamber into the second chamber through the channel between the leaflet FL and the mating surface 411c. In particular, the pad 411 is configured to avoid stenosis due to insufficient space between the FL leaflet and the mating surface 411c during diastole, such as the thickness of the pad 411 and / or its position relative to the leaflet FL.

[0065] In this implementation, since the pad 411 is held at a preset position between a pair of leaflets FL and SL and the mating surface 411d mates with the leaflet SL, the pad 411 affects the movement of the leaflet SL, and the leaflet SL reduces or loses its original physiological function. Compared with the foregoing implementation, if a treatment device according to this implementation is used, after a long service time, it may have a certain impact on the structure and function of the leaflet SL. Of course, in the functional role of the entire valve, the leaflet FL plays a greater role than the leaflet SL.

[0066] Figure 6 FIG. is a schematic structural view of a cardiac implant 500 according to another embodiment of the present disclosure located within a patient's heart.

[0067] See Figure 6 , the cardiac implant 500 includes a treatment device 510 and a pair of sensors 520a, 520b. The treatment device 510 includes a mating member 511 and a pair of paddles 512a, 512b, and the pair of paddles 512a, 512b are respectively located on opposite sides of the mating member 511.

[0068] After the cardiac implant 500 is implanted into a patient's heart, the pair of paddles 512a, 512b are configured to hold the mating member 511 between a pair of leaflets FL, SL. In one example, each paddle may have a clip-like configuration to clamp onto the corresponding leaflet, thereby positioning the mating member 511 between the pair of leaflets FL, SL. In another example, each paddle may cooperate with the mating member 511 to clamp the corresponding leaflet therebetween, thereby positioning the mating member 511 between the pair of leaflets FL, SL. It should be understood that the specific implementation of the pair of paddles 512a, 512b may refer to the related art, and for the sake of brevity, it will not be elaborated here.

[0069] When the second chamber is in diastole, the pair of leaflets FL, SL form a double orifice on both sides of the mating member 511; at this time, the valve opens and blood flow can flow from the first chamber into the second chamber. When the second chamber is in systole, the pair of leaflets FL, SL are properly mated on both sides of the mating member 511; at this time, the valve closes properly, thereby preventing blood from flowing back.

[0070] The mating member 511 has a top surface 511a facing the first chamber, and the treatment device 510 has a bottom surface 510a facing the second chamber. The pair of sensors 520a, 520b can be a pair of pressure sensors. The pair of pressure sensors 520a, 520b can be respectively attached to the top surface 511a of the mating member and the bottom surface 510a of the treatment device 510 to respectively sense the blood pressures in the first chamber and the second chamber.

[0071] Pressure sensors 520a and 520b can respectively sense the blood pressure throughout the cardiac cycle in the first chamber and the second chamber, providing hemodynamic information of diagnostic value to doctors. This information plays an important role in evaluating the overall function of the heart, as well as the working conditions of valves and implants. At the same time, the pressure information can also help doctors evaluate the placement position of the implant during the implantation process and make a real-time assessment of whether there is an obstruction to the diastolic blood flow into the second chamber, thus better ensuring the success of the implantation surgery and achieving better clinical effects.

[0072] When the valve is open, the blood flow from the first chamber to the second chamber impacts almost directly on the diaphragm of the pressure sensor 520a attached to the top 511a, enabling the physiological information (i.e., pressure information) sensed by the pressure sensor 520a to relatively accurately reflect whether the blood flow from the first chamber to the second chamber is normal, and thus relatively accurately reflect whether there is a stenosis problem with the patient's valve after the cardiac implant 500 is implanted.

[0073] When the valve is closed, if there is still a backflow from the second chamber to the first chamber, the backflow will impact almost directly on the diaphragm of the pressure sensor 520b attached to the bottom 510a, so that the physiological information and changes (i.e., pressure information) generated by the blood flow sensed by the sensor 520b, including reflecting whether there is a backflow from the second chamber to the first chamber.

[0074] Thus, by attaching a pair of pressure sensors 520a and 520b to the top 511a and the bottom 510a of the mating part 511 respectively, it is possible to relatively accurately detect whether there is a stenosis problem or a backflow problem with the valve after the cardiac implant 500 is implanted, and thus relatively accurately monitor the patient's postoperative recovery degree and the development of the condition.

[0075] It should be noted that in other examples, the cardiac implant 500 may also include only the sensor 520a attached to the top 511a, or may include only the sensor 520b attached to the bottom 510a. Of course, in other examples, the cardiac implant 500 may also include more sensors.

[0076] It should also be noted that in other examples, one or more sensors may also be attached to other parts of the treatment device 500. For example, in some examples, one or more sensors may be attached to the side of the mating part 511.

[0077] It should also be noted that in other examples, the sensors of the cardiac implant 500 may also be sensors capable of sensing other physiological information.

[0078] It should be understood that the term "comprising" and its variations used in the present disclosure are open-ended, that is, "including but not limited to". The term "one embodiment" means "at least one embodiment", and the term "another embodiment" means "at least one additional embodiment".

[0079] It should be understood that although terms such as "first" or "second" may be used in the present disclosure to describe various elements (such as the first chamber and the second chamber), these elements are not limited by these terms, and these terms are only used to distinguish one element from another.

[0080] It should be noted that the various specific technical features (elements) described in the above specific embodiments can be combined in any appropriate manner without conflict. To avoid unnecessary repetition, the present disclosure will not separately describe various possible combination methods.

[0081] It should be understood that multiple components and / or parts can be provided by a single integrated component or part. Alternatively, a single integrated component or part can be divided into multiple separate components and / or parts. The disclosure of "a" or "one" used to describe a component or part does not mean to exclude other components or parts.

[0082] As described above, the above are only the specific embodiments of the present disclosure, but the protection scope of the present disclosure is not limited thereto. Any person skilled in the art within the technical scope disclosed by the present disclosure can think of changes or substitutions, which should be covered by the protection scope of the present disclosure. Therefore, the protection scope of the present disclosure should be subject to the protection scope of the claims.

Claims

1. A cardiac implant adapted to be implanted in a patient's heart, the heart including a first chamber, a second chamber, and a valve for periodically allowing blood to flow from the first chamber into the second chamber, characterized in that, The heart implant includes a treatment device and at least one sensor. The treatment device includes a support member and a pad. The support member is configured to be located in the first chamber and connected to the pad. The valve includes a pair of leaflets. The pad is configured to be located between the pair of leaflets and cause the valve to open and close periodically by cooperating with the pair of leaflets. The treatment device is used to repair the function of the valve to prevent blood from flowing back from the second chamber to the first chamber. The at least one sensor is attached to the treatment device and used to sense the physiological information of the patient; The at least one sensor includes a first pressure sensor. The first pressure sensor and the pad are attached to one side of the support member facing the second chamber and are arranged staggeredly.

2. The cardiac implant according to claim 1, characterized in that, The at least one sensor further includes at least one second pressure sensor. The at least one second pressure sensor is attached to the pad.

3. The cardiac implant according to claim 2, characterized in that, The pad has a top surface configured to face the first chamber. The at least one second pressure sensor includes one second pressure sensor. The one second pressure sensor is attached to the top surface of the pad to sense the blood pressure in the first chamber.

4. The cardiac implant according to claim 2, characterized in that, The pad has a bottom surface configured to face the second chamber. The at least one second pressure sensor includes one second pressure sensor. The one second pressure sensor is attached to the bottom surface of the pad to sense the blood pressure in the second chamber.

5. The cardiac implant according to claim 2, characterized in that, The pad has a top surface configured to face the first chamber and a bottom surface configured to face the second chamber. The at least one second pressure sensor includes a pair of second pressure sensors. The pair of second pressure sensors are respectively attached to the top surface and the bottom surface of the pad to respectively sense the blood pressures in the first chamber and the second chamber.

6. The cardiac implant according to claim 2, wherein The support member is configured to be located in the first chamber and connected to the pad to position the pad between the pair of leaflets.

Images